A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Bhumsuk Keam, Keun-Wook Lee, Se-Hoon Lee, Jin-Soo Kim, Jin Ho Kim, Hong-Gyun Wu, Keun-Yong Eom, Suzy Kim, Soon-Hyun Ahn, Eun-Jae Chung, Seong Keun Kwon, Woo-Jin Jeong, Young Ho Jung, Ji-Won Kim, Dae Seog Heo, Bhumsuk Keam, Keun-Wook Lee, Se-Hoon Lee, Jin-Soo Kim, Jin Ho Kim, Hong-Gyun Wu, Keun-Yong Eom, Suzy Kim, Soon-Hyun Ahn, Eun-Jae Chung, Seong Keun Kwon, Woo-Jin Jeong, Young Ho Jung, Ji-Won Kim, Dae Seog Heo

Abstract

Lessons learned: Induction chemotherapy with Genexol-PM and cisplatin demonstrated modest tumor response in locally advanced head and neck squamous cell carcinoma.Considering favorable toxicity profiles and promising survival data, further studies on this regimen are warranted in patients with head and neck squamous cell carcinoma.

Background: Genexol-PM is a polymeric micellar formulation of paclitaxel without Cremophor EL. We investigated the efficacy and safety of Genexol-PM plus cisplatin as induction chemotherapy (IC) in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC).

Methods: Patients received Genexol-PM (230 mg/m2) and cisplatin (60 mg/m2) every 3 weeks as IC. After three cycles of IC, definitive treatment of either concurrent chemoradiotherapy (CCRT) with weekly cisplatin (30 mg/m2) or surgery was performed. The primary endpoint was overall response rate (ORR) after IC.

Results: Of 52 patients enrolled, 47 completed three cycles of IC, and the ORR was 55.8% (95% confidence interval, 42.3-69.3). Although there was one treatment-related death, toxicity profiles to Genexol-PM and cisplatin were generally favorable, and the most common grade 3 or 4 toxicities were neutropenia (15.4%), anorexia (7.7%), and general weakness (7.7%). Fifty-one patients received definitive treatment (CCRT [n = 44] or radical surgery [n = 7]). The rate of complete response following CCRT was 81.8% (36/44). After a median follow-up of 39 months, estimates of progression-free survival (PFS) and overall survival (OS) at 3 years were 54.3% and 71.3%, respectively.

Conclusion: IC with Genexol-PM and cisplatin demonstrated modest tumor response with well-tolerated toxicity profiles for patients with LA-HNSCC.

Trial registration: ClinicalTrials.gov NCT01689194.

© AlphaMed Press; the data published online to support this summary are the property of the authors.

Figures

Figure 1.
Figure 1.
Waterfall plots of best percentage changes in the sum of the longest diameters of target lesions. Abbreviation: PR, partial response.
Figure 2.
Figure 2.
Kaplan‐Meier curve for progression‐free survival.
Figure 3.
Figure 3.
Kaplan‐Meier curve for overall survival.

References

    1. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–216.
    1. Pignon JP, Bourhis J, Domenge C et al. Chemotherapy added to locoregional treatment for head and neck squamous‐cell carcinoma: Three meta‐analyses of updated individual data. MACH‐NC Collaborative Group. Meta‐Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949–955.
    1. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008;359:1143–1154.
    1. Pignon JP, le Maitre A, Maillard E et al. Meta‐analysis of chemotherapy in head and neck cancer (MACH‐NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:4–14.
    1. Kim R, Hahn S, Shin J et al. The effect of induction chemotherapy using docetaxel, cisplatin, and fluorouracil on survival in locally advanced head and neck squamous cell carcinoma: A meta‐analysis. Cancer Res Treat 2016;48:907–916.
    1. Ghi MG, Paccagnella A, Ferrari D et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II‐III trial. Ann Oncol 2017;28:2206–2212.
    1. Hitt R, Lopez‐Pousa A, Martinez‐Trufero J et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005;23:8636–8645.
    1. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705–1715.
    1. Vermorken JB, Remenar E, van Herpen C et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695–1704.
    1. Kim TY, Kim DW, Chung JY et al. Phase I and pharmacokinetic study of Genexol‐PM, a cremophor‐free, polymeric micelle‐formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004;10:3708–3716.
    1. Lim WT, Tan EH, Toh CK et al. Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol‐PM) in patients with solid tumors. Ann Oncol 2010;21:382–388.
    1. Kim DW, Kim SY, Kim HK et al. Multicenter phase II trial of Genexol‐PM, a novel Cremophor‐free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non‐small‐cell lung cancer. Ann Oncol 2007;18:2009–2014.
    1. Kim HS, Lee JY, Lim SH et al. A prospective phase II study of cisplatin and Cremophor EL‐free paclitaxel (Genexol‐PM) in patients with unresectable thymic epithelial tumors. J Thorac Oncol 2015;10:1800–1806.
    1. Lee SW, Kim YM, Cho CH et al. An open‐label, randomized, parallel, phase II trial to evaluate the efficacy and safety of a Cremophor‐Free polymeric micelle formulation of paclitaxel as first‐line treatment for ovarian cancer: A Korean Gynecologic Oncology Group Study (KGOG‐3021). Cancer Res Treat 2018;50:195–203
    1. Park IH, Sohn JH, Kim SB et al. An open‐label, randomized, parallel, phase III trial evaluating the efficacy and safety of polymeric micelle‐formulated paclitaxel compared to conventional Cremophor EL‐based paclitaxel for recurrent or metastatic HER2‐negative breast cancer. Cancer Res Treat 2017;49:569–577.
    1. Blanchard P, Bourhis J, Lacas B et al. Taxane‐cisplatin‐fluorouracil as induction chemotherapy in locally advanced head and neck cancers: An individual patient data meta‐analysis of the meta‐analysis of chemotherapy in head and neck cancer group. J Clin Oncol 2013;31:2854–2860.
    1. Ock CY, Keam B, Lim Y et al. Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience. Head Neck 2016;38:277–284.
    1. Cohen EE, Karrison TG, Kocherginsky M et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol 2014;32:2735–2743.
    1. Haddad R, O'Neill A, Rabinowits G et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): A randomised phase 3 trial. Lancet Oncol 2013;14:257–264.
    1. Hitt R, Grau JJ, Lopez‐Pousa A et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol 2014;25:216‐225.
    1. Lee KW, Koh Y, Kim SB et al. A randomized, multicenter, phase II study of cetuximab with docetaxel and cisplatin as induction chemotherapy in unresectable, locally advanced head and neck cancer. The Oncologist 2015;20:1119–1120.
    1. Takacsi‐Nagy Z, Hitre E, Remenar E et al. Docetaxel, cisplatin and 5‐fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III‐IV unresectable head and neck cancer: Results of a randomized phase II study. Strahlenther Onkol 2015;191:635–641.
    1. Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24–35.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir